Clinical Trials

165 enrolled 13 charts

COVID-19, Papillomavirus Infections

NCT06632912 2026-01-23

Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging

1,800 enrolled

Infections, Papillomavirus Infections

NCT05262010 2026-01-16

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Phase 3 Recruiting

13,500 enrolled

Papillomavirus Infections

NCT04772534 2025-05-30

V503-066

314 enrolled 12 charts

Papillomavirus Infections

NCT04708041 2025-04-20

V503-069

700 enrolled

Papillomavirus Infections

NCT04199689 2025-03-25

V503-049

6,033 enrolled

Papillomavirus Infections

NCT03903562 2025-03-24

V503-024

1,990 enrolled

Papillomavirus Infections

NCT00733122 2025-03-03

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Phase 3 Withdrawn

Papillomavirus Infections

NCT05285826 2024-12-16

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

8,100 enrolled

Papillomavirus Infections

NCT04895020 2024-04-17

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Phase 3 Recruiting

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Phase 3 Recruiting

1,348 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT06207175 2024-01-23

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Phase 3 Unknown

1,260 enrolled

Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT06041061 2023-09-18

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

18,000 enrolled

Papillomavirus Infections

NCT00380367 2023-05-31

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

110 enrolled 7 charts

Papillomavirus Infections

NCT04965350 2023-04-13

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

1,100 enrolled

Papillomavirus Infections

NCT05668572 2023-01-04

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Phase 3 Unknown

12,000 enrolled

Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

GastrointestinalGynecologic

2,750 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT03998254 2022-11-16

V503-023

6,000 enrolled

Papillomavirus Infections

NCT05450705 2022-09-02

V503-071

1,500 enrolled

Papillomavirus Infections

NCT05156541 2021-12-14

ING-HPV-1

30 enrolled

Condylomata Acuminata, Papillomavirus Infections

NCT00481767 2020-11-17

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

676 enrolled 15 charts

Infections, Papillomavirus Infections

NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

525 enrolled 24 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

1,447 enrolled 26 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

148 enrolled 28 charts

Papillomavirus Infections

NCT03546842 2020-02-25

V503-017

201 enrolled 11 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

152 enrolled 21 charts

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00250276 2020-01-02

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

798 enrolled 19 charts

Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

5,752 enrolled 42 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

1,106 enrolled 27 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

1,212 enrolled 15 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01462357 2019-11-15

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

1,079 enrolled 26 charts

Papillomavirus Infections

NCT01249365 2019-11-13

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

199 enrolled 9 charts

Papillomavirus Infections

NCT01190176 2019-10-30

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

34 enrolled 12 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00937950 2019-10-29

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

2,022 enrolled 10 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01190189 2019-06-19

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

137 enrolled 9 charts

Papillomavirus Infections

NCT00834106 2019-02-04

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

3,006 enrolled 17 charts

Papillomavirus Infections

NCT00988884 2018-12-14

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

1,241 enrolled 15 charts

Papillomavirus Infections

NCT01254643 2018-11-28

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

100 enrolled 8 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01073293 2018-11-27

A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

1,054 enrolled 15 charts

Papillomavirus Infections

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

250 enrolled 20 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT02114385 2018-11-01

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

500 enrolled 14 charts

Papillomavirus Infections

NCT00492544 2018-09-04

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

100 enrolled 9 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00122681 2018-08-20

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

18,729 enrolled 35 charts

Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

814 enrolled 28 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

744 enrolled 27 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01277042 2018-08-17

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

1,212 enrolled 14 charts

Papillomavirus Infections

NCT01984697 2018-08-08

V503-010

1,518 enrolled 44 charts

Papillomavirus Infections

NCT00344032 2018-07-20

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

354 enrolled 12 charts

Papillomavirus Infections

NCT00345878 2018-07-20

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

271 enrolled 12 charts